China NMPA Product Recall - Patient programmer and implantable neurostimulator charger kit

Medtronic (Shanghai) Management Co., Ltd. initiated a voluntary Class III recall, reported on January 19, 2017, and published by the National Medical Products Administration (NMPA) on February 21, 2017. The recall concerns specific charging kits for patient programmers and implantable neurostimulators (models 37746 and 37754). The primary issue identified was that these products were manufactured before the official approval dates of their required NMPA registration certificates in China. This action was taken to ensure compliance with Chinese medical device regulations, which mandate that products possess approved registration certificates prior to their production or import. Despite this regulatory non-compliance, Medtronic affirms that the affected products were manufactured strictly in accordance with production requirements, and their safety and efficacy remain unaffected. The recall is not driven by any defect or patient risk, but solely by administrative pre-approval requirements. As part of the corrective actions, Medtronic will issue notification letters to relevant parties and retrieve all unused affected products. A total of 11 units were produced or imported into China, with 9 units having been sold within the country. The recall highlights the importance of strict adherence to regional regulatory timelines for product market authorization.